- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01386385
Veliparibe com ou sem radioterapia, carboplatina e paclitaxel em pacientes com câncer de pulmão de células não pequenas em estágio III que não pode ser removido por cirurgia
Um estudo de descoberta de dose seguido por um estudo de fase II randomizado e controlado por placebo de Veliparib (ABT-888) adicionado à quimiorradioterapia com carboplatina e paclitaxel para câncer de pulmão de células não pequenas (NSCLC) de estágio III irressecável (estudo NCI número 8811)
This phase I/II partially randomized trial studies the side effects and best dose of veliparib when given together with radiation therapy, carboplatin, and paclitaxel and to see how well it works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether radiation therapy, carboplatin, and paclitaxel are more effective with or without veliparib in treating non-small cell lung cancer.
Visão geral do estudo
Status
Condições
- Adenocarcinoma pulmonar
- Carcinoma de Células Grandes do Pulmão
- Câncer de pulmão de células não pequenas estágio IIIA AJCC v7
- Adenocarcinoma Pulmonar Minimamente Invasivo
- Câncer de pulmão de células não pequenas estágio IIIB AJCC v7
- Câncer de pulmão de células não pequenas estágio III AJCC v7
- Carcinoma Espinocelular de Pulmão
- Adenocarcinoma pulmonar, subtipo misto
Descrição detalhada
PRIMARY OBJECTIVES:
I. To establish the maximum tolerated dose (MTD) and the recommended phase II dose of ABT-888 (veliparib) when given concurrently with standard carboplatin/paclitaxel and radiotherapy in patients with unresectable stage III non-small cell lung cancer (NSCLC). (Phase I) II. To assess whether carboplatin/paclitaxel plus ABT-888 compared with carboplatin/paclitaxel plus placebo improves progression-free survival (PFS) in patients with unresectable stage III NSCLC. (Phase II) III. To compare overall survival (OS) in patients treated with carboplatin/paclitaxel and radiotherapy plus ABT-888 to those treated with carboplatin, paclitaxel and radiotherapy plus placebo. (Phase II) IV. To assess the response rate (confirmed and unconfirmed, complete and partial responses) and disease control rate in the subset of patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. (Phase II) V. To assess the safety and toxicity profile of the regimen. (Phase II)
SECONDARY OBJECTIVES:
I. To collect tumor tissue from pretreatment biopsies (archival samples) for biomarker studies, including poly (ADP-ribose) polymerase 1 (PARP) activity by measuring the levels of poly-ADP-ribose, gamma-H2A histone family, member X (gamma-H2AX), and messenger ribonucleic acid (mRNA) expression levels of deoxyribonucleic acid (DNA) repair enzymes such as excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1)/x-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1).
II. To collect blood samples for evaluation of gamma-H2AX (circulating tumor cells) and other relevant future studies.
OUTLINE: This is a phase I, dose-escalation study of veliparib followed by a randomized phase II study.
PHASE I:
INDUCTION THERAPY: Patients undergo 3-dimensional conformal radiation therapy (3D-CRT) once daily (QD), 5 days a week, for 6 weeks. Patients also receive veliparib orally (PO) twice daily (BID) on days 1-43 and carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 36, and 43 in the absence of disease progression or unacceptable toxicity. Patients without disease progression after completion of chemoradiotherapy undergo consolidation therapy.
CONSOLIDATION THERAPY: Beginning within 4-6 weeks of chemotherapy and radiation therapy, patients receive veliparib PO BID on days 1-7 (course 1) and 22-28 (course 2) and carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1 and on day 22 of course 2. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
PHASE II: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy.
ARM II: Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
After completion of study treatment, patients are followed up every 4 months for first 2 years and then every 6 months until 5 years.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Estados Unidos, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Estados Unidos, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Estados Unidos, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Estados Unidos, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Beverly Hills, California, Estados Unidos, 90211
- Tower Cancer Research Foundation
-
Burbank, California, Estados Unidos, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Corona, California, Estados Unidos, 92882
- City of Hope Corona
-
Duarte, California, Estados Unidos, 91010
- City of Hope Comprehensive Cancer Center
-
Los Angeles, California, Estados Unidos, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Estados Unidos, 90033
- Los Angeles General Medical Center
-
Merced, California, Estados Unidos, 95340
- Mercy Cancer Center
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- UCHealth University of Colorado Hospital
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Estados Unidos, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Estados Unidos, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Estados Unidos, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Estados Unidos, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Estados Unidos, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Estados Unidos, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Estados Unidos, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Estados Unidos, 96826
- Kapiolani Medical Center for Women and Children
-
Lihue, Hawaii, Estados Unidos, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Estados Unidos, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Estados Unidos, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Estados Unidos, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Estados Unidos, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Estados Unidos, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Estados Unidos, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Estados Unidos, 60504
- Rush-Copley Medical Center
-
Bloomington, Illinois, Estados Unidos, 61704
- Illinois CancerCare-Bloomington
-
Bloomington, Illinois, Estados Unidos, 61701
- OSF Saint Joseph Medical Center
-
Canton, Illinois, Estados Unidos, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Estados Unidos, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Estados Unidos, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Estados Unidos, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Estados Unidos, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Danville, Illinois, Estados Unidos, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Estados Unidos, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Estados Unidos, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Estados Unidos, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Estados Unidos, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Estados Unidos, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Estados Unidos, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Estados Unidos, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Estados Unidos, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, Estados Unidos, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Estados Unidos, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Estados Unidos, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Estados Unidos, 61554
- Illinois CancerCare-Pekin
-
Pekin, Illinois, Estados Unidos, 61554
- OSF Saint Francis Radiation Oncology at Pekin
-
Peoria, Illinois, Estados Unidos, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Estados Unidos, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Estados Unidos, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Estados Unidos, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Peru, Illinois, Estados Unidos, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Estados Unidos, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Estados Unidos, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield Clinic
-
Springfield, Illinois, Estados Unidos, 62702
- Central Illinois Hematology Oncology Center
-
Springfield, Illinois, Estados Unidos, 62781
- Springfield Memorial Hospital
-
Swansea, Illinois, Estados Unidos, 62226
- Southwest Illinois Health Services LLP
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
Urbana, Illinois, Estados Unidos, 61801
- The Carle Foundation Hospital
-
Yorkville, Illinois, Estados Unidos, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Fort Wayne, Indiana, Estados Unidos, 46845
- Fort Wayne Medical Oncology and Hematology Inc-Parkview
-
Richmond, Indiana, Estados Unidos, 47374
- Reid Health
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic - Ames
-
Sioux City, Iowa, Estados Unidos, 51101
- Siouxland Regional Cancer Center
-
-
Kansas
-
Chanute, Kansas, Estados Unidos, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Estados Unidos, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Estados Unidos, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Estados Unidos, 66701
- Cancer Center of Kansas - Fort Scott
-
Garden City, Kansas, Estados Unidos, 67846
- Saint Catherine Hospital
-
Great Bend, Kansas, Estados Unidos, 67530
- Central Care Cancer Center - Great Bend
-
Hays, Kansas, Estados Unidos, 67601
- HaysMed
-
Independence, Kansas, Estados Unidos, 67301
- Cancer Center of Kansas-Independence
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Cancer Center
-
Kansas City, Kansas, Estados Unidos, 66112
- University of Kansas Cancer Center-West
-
Kingman, Kansas, Estados Unidos, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Estados Unidos, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Estados Unidos, 67905
- Cancer Center of Kansas-Liberal
-
Manhattan, Kansas, Estados Unidos, 66502
- Cancer Center of Kansas-Manhattan
-
McPherson, Kansas, Estados Unidos, 67460
- Cancer Center of Kansas - McPherson
-
Newton, Kansas, Estados Unidos, 67114
- Cancer Center of Kansas - Newton
-
Olathe, Kansas, Estados Unidos, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, Estados Unidos, 66210
- University of Kansas Cancer Center-Overland Park
-
Parsons, Kansas, Estados Unidos, 67357
- Cancer Center of Kansas - Parsons
-
Pittsburg, Kansas, Estados Unidos, 66762
- Mercy Hospital Pittsburg
-
Pratt, Kansas, Estados Unidos, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Estados Unidos, 67401
- Salina Regional Health Center
-
Salina, Kansas, Estados Unidos, 67401
- Cancer Center of Kansas - Salina
-
Topeka, Kansas, Estados Unidos, 66606
- University of Kansas Health System Saint Francis Campus
-
Wellington, Kansas, Estados Unidos, 67152
- Cancer Center of Kansas - Wellington
-
Westwood, Kansas, Estados Unidos, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, Estados Unidos, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Estados Unidos, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Estados Unidos, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Estados Unidos, 67208
- Associates In Womens Health
-
Wichita, Kansas, Estados Unidos, 67214
- Wesley Medical Center
-
Winfield, Kansas, Estados Unidos, 67156
- Cancer Center of Kansas - Winfield
-
-
Massachusetts
-
Burlington, Massachusetts, Estados Unidos, 01805
- Lahey Clinic
-
-
Michigan
-
Battle Creek, Michigan, Estados Unidos, 49017
- Bronson Battle Creek
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Estados Unidos, 48201
- Wayne State University/Karmanos Cancer Institute
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Estados Unidos, 49007
- West Michigan Cancer Center
-
Muskegon, Michigan, Estados Unidos, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Estados Unidos, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Reed City, Michigan, Estados Unidos, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Estados Unidos, 49684
- Munson Medical Center
-
Wyoming, Michigan, Estados Unidos, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Bemidji, Minnesota, Estados Unidos, 56601
- Sanford Joe Lueken Cancer Center
-
-
Mississippi
-
Southhaven, Mississippi, Estados Unidos, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Ballwin, Missouri, Estados Unidos, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bonne Terre, Missouri, Estados Unidos, 63628
- Parkland Health Center-Bonne Terre
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Mercy Cancer Center - Cape Girardeau
-
Jefferson City, Missouri, Estados Unidos, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Estados Unidos, 64804
- Freeman Health System
-
Joplin, Missouri, Estados Unidos, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Estados Unidos, 64128
- Kansas City Veterans Affairs Medical Center
-
Kansas City, Missouri, Estados Unidos, 64154
- University of Kansas Cancer Center - North
-
Kansas City, Missouri, Estados Unidos, 64131
- The University of Kansas Cancer Center-South
-
Kansas City, Missouri, Estados Unidos, 64108
- University Health Truman Medical Center
-
Lee's Summit, Missouri, Estados Unidos, 64064
- University of Kansas Cancer Center - Lee's Summit
-
Rolla, Missouri, Estados Unidos, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Estados Unidos, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Estados Unidos, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Estados Unidos, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Estados Unidos, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Estados Unidos, 63141
- Mercy Hospital Saint Louis
-
Sullivan, Missouri, Estados Unidos, 63080
- Missouri Baptist Sullivan Hospital
-
Washington, Missouri, Estados Unidos, 63090
- Mercy Hospital Washington
-
-
Montana
-
Anaconda, Montana, Estados Unidos, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Estados Unidos, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Estados Unidos, 59405
- Great Falls Clinic
-
Great Falls, Montana, Estados Unidos, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Estados Unidos, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Estados Unidos, 59901
- Logan Health Medical Center
-
Missoula, Montana, Estados Unidos, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Estados Unidos, 59804
- Community Medical Center
-
-
North Carolina
-
Hendersonville, North Carolina, Estados Unidos, 28791
- Margaret R Pardee Memorial Hospital
-
Kinston, North Carolina, Estados Unidos, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Estados Unidos, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
-
North Dakota
-
Bismarck, North Dakota, Estados Unidos, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Estados Unidos, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Estados Unidos, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44708
- Cleveland Clinic Mercy Hospital
-
Centerville, Ohio, Estados Unidos, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Estados Unidos, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, Estados Unidos, 45236
- Oncology Hematology Care Inc-Kenwood
-
Dayton, Ohio, Estados Unidos, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, Estados Unidos, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Estados Unidos, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Estados Unidos, 45415
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Estados Unidos, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Estados Unidos, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Estados Unidos, 45840
- Orion Cancer Care
-
Franklin, Ohio, Estados Unidos, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Estados Unidos, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Estados Unidos, 45331
- Wayne Hospital
-
Greenville, Ohio, Estados Unidos, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Estados Unidos, 45429
- Kettering Medical Center
-
Kettering, Ohio, Estados Unidos, 45409
- Greater Dayton Cancer Center
-
Middletown, Ohio, Estados Unidos, 45042
- Dayton Physicians LLC-Signal Point
-
Sidney, Ohio, Estados Unidos, 45365
- Dayton Physicians LLC-Wilson
-
Springfield, Ohio, Estados Unidos, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Estados Unidos, 45504
- Springfield Regional Medical Center
-
Troy, Ohio, Estados Unidos, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Estados Unidos, 45373
- Dayton Physicians LLC - Troy
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Estados Unidos, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Estados Unidos, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Estados Unidos, 97420
- Bay Area Hospital
-
Newberg, Oregon, Estados Unidos, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Estados Unidos, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Estados Unidos, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Estados Unidos, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Reading, Pennsylvania, Estados Unidos, 19605
- Penn State Health Saint Joseph Medical Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Estados Unidos, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Estados Unidos, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- UT MD Anderson Cancer Center
-
San Antonio, Texas, Estados Unidos, 78229
- University Hospital
-
San Antonio, Texas, Estados Unidos, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Estados Unidos, 78229
- Audie L Murphy VA Hospital
-
-
Washington
-
Aberdeen, Washington, Estados Unidos, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Estados Unidos, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Estados Unidos, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Estados Unidos, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Estados Unidos, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Estados Unidos, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Estados Unidos, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Estados Unidos, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Estados Unidos, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, Estados Unidos, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Estados Unidos, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Estados Unidos, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Estados Unidos, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Shelton, Washington, Estados Unidos, 98584
- Providence Regional Cancer System-Shelton
-
Spokane, Washington, Estados Unidos, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, Estados Unidos, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
Spokane Valley, Washington, Estados Unidos, 99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Vancouver, Washington, Estados Unidos, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Estados Unidos, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Estados Unidos, 98597
- Providence Regional Cancer System-Yelm
-
-
Wyoming
-
Cody, Wyoming, Estados Unidos, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Estados Unidos, 82801
- Welch Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Patients must have histologically or cytologically-proven new diagnosis of unresectable stage IIIA/IIIB*, non-small cell lung cancer (adenocarcinoma, bronchioloalveolar cell carcinoma, large cell carcinoma, squamous cell carcinoma, or mixed)
- Per the American Joint Committee on Cancer (AJCC) 7th edition, pleural and pericardial are now considered stage M1a disease; when pleural fluid is visible on the computed tomography (CT) scan or on a chest x-ray, a thoracentesis is required to confirm that the pleural fluid is cytologically negative; patients with exudative pleural effusions are excluded, regardless of cytology; patients with effusions that are minimal (i.e. not visible on chest x-ray) that are too small to safely tap are eligible; a small effusion that has positive fludeoxyglucose F 18 (FDG) uptake on positron emission tomography (PET) has to be proven to be malignant per standard of care diagnostic procedures for the patient to be excluded
-
Patients must have measurable or non-measurable disease documented by CT, magnetic resonance imaging (MRI) or PET/CT; the CT from a combined PET/CT may be used to document only non-measurable disease unless the scan is of diagnostic quality; measurable disease must be assessed by CT within 28 days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
-
Patients with brain metastases are ineligible; all patients must have a pretreatment CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to registration
-
Patients must not have received any prior systemic therapy (chemotherapy or other biologic therapy) for lung cancer
-
Patients must not have received prior chest radiation therapy for NSCLC
-
Patients must not have had a previous surgical resection; however, patients may have undergone exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar surgery for the purpose of determining the diagnosis, stage or potential resectability of newly diagnosed lung tumor; at least 28 days must have elapsed since thoracic surgery (excluding mediastinoscopy or other minor surgeries) and patients should have recovered from all associated toxicities at the time of registration; patients must not be planning to undergo a minor surgical procedure while on this study
-
Patients must have Zubrod performance status 0-1
-
Patients must have tumor tissue available for submission to assess gene expression of ERCC1 and XRCC1; patients must also be offered participation in banking for future use of specimens
-
Absolute neutrophil count >= 1,500/mcl
-
Platelets >= 100,000/mcl
-
Hemoglobin >= 9.0 g/dl
-
Total bilirubin within institutional upper limit of normal (IULN)
-
Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x IULN
-
Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
-
Patients must have a serum creatinine =< the IULN AND measured or calculated creatinine clearance >= 60 cc/min using the Cockroft-Gault formula
-
Patients must have pulmonary function tests (PFTs) including forced expiratory volume in 1 second (FEV1) within 84 days prior to registration; for FEV1, the best value obtained pre- or post-bronchodilator must be >= 1.2 liters/second and/or >= 50% predicted
-
Patients may not be planning to receive any other investigational agents
-
Patients must not have more than 10% weight loss in the past 6 months
-
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in study
-
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
-
Patient must not have any uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Patients must not currently have a > grade 1 symptomatic neuropathy-sensory (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.0)
-
Patients must not have a history of seizures
-
Patients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the study
-
Patients must be able to swallow whole capsules
-
Prestudy history and physical must be obtained within 28 days prior to registration
-
All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
-
As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY:
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have completed chemoradiotherapy per protocol and at least four weeks but no more than six weeks must have elapsed from the last day of induction therapy (the last day of radiation)
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have undergone restaging tests according to the study calendar and determined to have no evidence of disease progression
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have a serum creatinine =< (IULN) AND measured of calculated creatinine clearance >= 60 cc/min using the Cockroft-Gault formula
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Absolute neutrophil count >= 1,500 mcl
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Platelets >= 100,000/mcl
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Hemoglobin >= 9.0 g/dl
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Total bilirubin =< IULN
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: SGOT (AST) or SGPT (ALT) =< 2.5 x IULN
-
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have Zubrod performance status 0-1
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm I (RT, veliparib, carboplatin, paclitaxel)
Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy. |
Given IV
Outros nomes:
Given IV
Outros nomes:
Correlative studies Given PO
Outros nomes:
Undergo 3D-conformal RT
Outros nomes:
|
|
Comparador Ativo: Arm II (3D-CRT, placebo, carboplatin, paclitaxel)
Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I. |
Given IV
Outros nomes:
Given IV
Outros nomes:
Correlative studies Given PO Undergo 3D-conformal RT
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Maximum Tolerated Dose of Veliparib When Given Concurrently With Standard Carboplatin/Paclitaxel and Radiotherapy, Determined According to Incidence of Dose Limiting Toxicity (DLT) (Phase I)
Prazo: 9 weeks
|
DLTs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. DLTs must be attributable (probably, possibly, definitely related) to the study regimen and only occur during RT or 2 weeks after completing RT. DLTs are defined as:
|
9 weeks
|
|
Progression-free Survival of Patients Treated With Chemoradiotherapy Plus Veliparib (Phase II)
Prazo: The time from randomization to progression or death due to any cause, assessed up to 5 years
|
Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause. Participants last known to be alive are censored at date of last contact. Assessed by Response Evaluation Criteria in Solid Tumors, RECIST 1.1 |
The time from randomization to progression or death due to any cause, assessed up to 5 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Survival (Phase II)
Prazo: Up to 5 years
|
From date of registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact. |
Up to 5 years
|
|
Objective Response Rate (Phase II)
Prazo: Up to 5 years
|
ORR is defined as the percentage of participants with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 |
Up to 5 years
|
|
Incidence of Serious (>= Grade 3) Adverse Events as Measured by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Phase II)
Prazo: Duration of treatment and follow up until death or 5 years post registration
|
Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. |
Duration of treatment and follow up until death or 5 years post registration
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Athanassios (Ethan) Argiris, SWOG Cancer Research Network
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Neoplasias Pulmonares
- Carcinoma
- Adenocarcinoma de Pulmão
- Adenocarcinoma Brônquio-Alveolar
- Produtos químicos orgânicos
- Terapêutica
- Hidrocarbonetos
- Cicloparaffinas
- Hidrocarbonetos, aliciclicos
- Hidrocarbonetos, cíclicos
- Terpenos
- Complexos de coordenação
- Taxóides
- Ciclodecanos
- Diterpenos
- Economia de saúde e organizações
- Radioterapia
- Radioterapia, assistida por computador
- Economia
- Carboplatina
- Paclitaxel
- Veliparibe
- Radioterapia, conforme
- Impostos
Outros números de identificação do estudo
- NCI-2011-02592
- U10CA032102 (Concessão/Contrato do NIH dos EUA)
- U10CA180888 (Concessão/Contrato do NIH dos EUA)
- N01CM62209 (Concessão/Contrato do NIH dos EUA)
- 8811 (Outro identificador: CTEP)
- NCI-2011-02592 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- CHNMC-PHII-111
- CDR0000701003
- PHII-111
- S1206
- 8811 (Outro identificador: SWOG)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .